Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AGM Statement

14th Jul 2010 07:00

RNS Number : 2951P
Cyprotex PLC
14 July 2010
 



Wednesday 14 July 2010

 

 

Cyprotex PLC

("Cyprotex" or the "Company")

 

AGM Statement

 

 

Cyprotex (AIM:CRX), the drug discovery technology and information company, will hold its Annual General meeting today. At that meeting, Steve Harris, Chairman, will make the following comments:

 

"In 2009 we delivered a resilient performance in a difficult market. Revenues hit £5m for the second successive year and we also delivered our second year of profitability. We doubled the number of strategic customers and added 20 new customers in total.

 

"In the current year, Cyprotex has experienced a strong second quarter and this momentum has continued into July. The Company's revenue and EBITDA performance is in line with market expectations. Furthermore, the Company will open a new laboratory in the coming weeks which will double capacity and allow the launch of our new toxicology offerings."

 

Cyprotex expects to announce its interim results for the six months to 30 June 2010 on Thursday 12 August 2010.

 

 

 

For further information:

 

Cyprotex PLC

Tel: +44 (0) 1625 505 100

Dr Anthony Baxter, Chief Executive Officer

John Dootson, Chief Financial Officer

[email protected]

www.cyprotex.com

Singer Capital Markets Ltd

Tel: +44 203 205 7500 

Shaun Dobson

Claes Spång

www.singercm.com

Financial Dynamics

Tel: +44 (0) 20 7831 3113

Ben Brewerton / Ben Atwell / Mo Noonan

[email protected]

www.fd.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMEXLFFBDFXBBK

Related Shares:

CRX.L
FTSE 100 Latest
Value8,275.66
Change0.00